DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity

Nissen, Mette S.; Beier, Christoph P.

Published in:
Neurology: Genetics

DOI:
10.1212/NXG.0000000000000272

Publication date:
2018

Document version
Final published version

Document license
CC BY-NC-ND

Citation for published version (APA):
Nissen, M. S., & Beier, C. P. (2018). DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity. Neurology: Genetics, 4(5), [e272]. https://doi.org/10.1212/NXG.0000000000000272

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk
Phenytoin is a first-generation antiepileptic drug, which is used in the treatment of focal seizures and as standard of care for patients with benzodiazepine-refractory status epilepticus. Elimination of phenytoin occurs primarily via CYP enzyme–dependent hepatic clearance. The first step is the para-hydroxylation from active phenytoin to inactive hydroxy-phenytoin, which is dependent on CYP2C9 and, to a lesser extent, on CYP2C19. A considerable disparity in CYP2C9 alleles exists, and the frequency varies among different ancestry groups, the CYP2C9*3 allele being less frequent in Caucasians and more frequent in Asian populations. Homozygosity for the CYP2C9*3 allele leads to a significant reduction in enzyme activity, resulting in increased plasma levels of phenytoin.

Severe cutaneous adverse drug reactions (SCARs) such as Steven Johnson syndrome, toxic epi- dermal necrolysis, or drug reaction with eosinophilia and systemic symptoms (DRESS) are known complications of phenytoin treatment. The pharmacogenetic basis of SCARs due to phenytoin treatment is not yet fully understood. Certain human leukocyte antigen (HLA) subtypes (e.g., HLA-B*13:01, HLA-B*56:02/04) are associated in some Asian populations with an increased risk of developing SCARs, however, the association is less pronounced as compared to carbamazepine. In 2014, CYP2C9 polymorphism (CYP2C9*3) was first described as a new and highly significantly associated nonimmunologic genetic risk factor for SCARs in a Japanese population.

Case report

Here, we report a case of DRESS after IV administered phenytoin in a patient with CYP2C9*3 homozygosity. The 54-year-old, non-consanguineous, female refugee from northern Iran (and born in Pakistan) presented to the neurologic department at the Odense University Hospital (Denmark) with a first-time bilateral tonic-clonic seizure, with subsequent series of focal seizures with impaired consciousness, fulfilling status epilepticus criteria. Treatment with 10 mg of IV diazepam remained ineffectiv. Fosphenytoin (20 mg phenytoin-equivalents/kg) was adminis-tered IV, and the seizures were terminated. As per protocol, the patient received a maintenance dose of phenytoin 100 mg q8h. MRI of the brain revealed sequela after traumatic brain injury in the left frontal lobe as likely epileptic focus; routine blood tests were normal. Two days after admission, the patient developed nystagmus, ataxia, vertigo, nausea, and universal pruritus. Blood tests revealed plasma phenytoin levels equal to phenytoin poisoning. Despite initial reduction and termination of the maintenance dose of phenytoin, plasma levels continued to increase in the following days, reaching a maximum of 142 μM (35.8 μg/mL) 4 days after the first administration. At day 8, the patient developed SCARs that fulfilled the RegiSCAR criteria for DRESS. She developed fever (39.5°C), hypotension, acute rash (figure, A), leukocytosis, liver abnor-malities (alanine transaminase > 400 U/L), and lymphadenopathy. PET-CT 10 days after the start of symptoms revealed universal lymphadenopathy (figure, B), resembling lymphoma. Liver biopsy showed inflammation compatible with hepatotoxicity. Skin biopsy showed inflammation, but with no significant eosinophilia. The patient’s antiepileptic treatment was changed to levetiracetam.
After 2 weeks, the symptoms slowly started to remit as the plasma levels of phenytoin normalized, and after 4 weeks, the patient was fully recovered. A control PET-CT was performed 6 weeks after debut of the symptoms to rule out lymphoma; the lymphadenopathy had completely resolved (figure, C). Genetic testing revealed homozygosity for the P450 CYP2C9*3 allele. The HLA types were HLA-A 30:68 and HLA-B 14:15.

Discussion

Plasma phenytoin levels are greatly affected by CYP2C9 polymorphisms. It is estimated that roughly 5% of the Scandinavian population are heterozygous for CYP2C9*3 allele; however, the prevalence is substantially higher in India and in the Middle East, where up to 16% carry a CYP2C9*3 allele, resulting in a higher proportion of homozygous patients (up to 1.6% in India). In several Asian populations, the CYP2C9*3 allele was associated with SCARs such as DRESS. The ethnic differences may be due to immunologic differences that are also seen in analyses focusing on HLA subtypes associated with SCARs. Our patient’s history illustrates the impressive systemic and cutaneous side effects of phenytoin associated with CYP2C9*3 homozygosity in this Asian patient. It stresses the importance of being aware of interacial genetic variability that can result in substantially increased risk of intoxication and greater risk of developing severe side effects such as SCARs. For practical purposes, genetic screening before IV phenytoin treatment is not feasible. Increasing phenytoin plasma concentrations despite dose reductions, as seen in this patient, has to prompt precaution and eventually rapid change of the antiepileptic treatment. In patients with established homozygosity for the P450 CYP2C9*3 allele, phenytoin treatment should be avoided.

Author contributions

M.S. Nissen and C.P. Beier treated the patient and wrote and finally approved the manuscript.

Study funding

The study was supported by the Region of Southern Denmark to C.P.B. (17/18517).

Disclosure

M.S. Nissen reports no disclosures. C.P. Beier served on the scientific advisory boards of UCB and Eisai; received speaker honoraria from UCB and Eisai; and received research support from UCB, Eisai, Novartis, Pfizer, and the Region of Southern Denmark. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NG.

Received April 30, 2018. Accepted in final form July 26, 2018.

References

1. Gaikwad T, Ghosh K, Shetty S. VKORC1 and CYP2C9 genotype distribution in Asian countries. Thromb Res 2014;134:537–544.
2. Pedersen RS, Verstuyft C, Becquemont L, Jaillon P, Bøsen K. Cytochrome P450 2C9 (CYP2C9) genotypes in a Nordic population in Denmark. Basic Clin Pharmacol Toxicol 2004;94:151–152.
3. Silvado CE, Terra VC, Twardowschy CA. CYP2C9 polymorphisms in epilepsy: influence on phenytoin treatment. Pharmacogenomics Pers Med 2018;11:51–58.
4. Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoin-related severe cutaneous adverse reactions. JAMA 2014;312:525–534.
5. Kardaun SH, Sekula P, Valerie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071–1080.
6. Tassaneeyakul W, Prabmeechai N, Sukasem C, et al. Associations between HLA class I and cytochrome P450 2C9 genetic polymorphisms and phenytoin-related severe cutaneous adverse reactions in a Thai population. Pharmacogenet Genomics 2016;26:225–234.
7. McCormack M, Urban TJ, Shianna KV, et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics 2012;13:399–405.
DRESS after IV phenytoin associated with cytochrome P450 CYP2C9*3 homozygosity
Mette S. Nissen and Christoph P. Beier

Neurol Genet 2018;4;
DOI 10.1212/NXG.0000000000000272

This information is current as of September 19, 2018

| Updated Information & Services | including high resolution figures, can be found at: http://ng.neurology.org/content/4/5/e272.full.html |
|-------------------------------|--------------------------------------------------------------------------------------------------|
| References                    | This article cites 7 articles, 0 of which you can access for free at: http://ng.neurology.org/content/4/5/e272.full.html##ref-list-1 |
| Subspecialty Collections      | This article, along with others on similar topics, appears in the following collection(s): Antiepileptic drugs http://ng.neurology.org/cgi/collection/antiepileptic_drugs Status epilepticus http://ng.neurology.org/cgi/collection/status_epilepticus |
| Permissions & Licensing       | Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://ng.neurology.org/misc/about.xhtml#permissions |
| Reprints                      | Information about ordering reprints can be found online: http://ng.neurology.org/misc/addir.xhtml#reprintsus |

Neurol Genet is an official journal of the American Academy of Neurology. Published since April 2015, it is an open-access, online-only, continuous publication journal. Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Online ISSN: 2376-7839.